These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 6178461)

  • 1. Impact of maternal serum alpha-fetoprotein screening on antenatal diagnosis.
    Brock DJ
    Br Med J (Clin Res Ed); 1982 Jul; 285(6338):365-7. PubMed ID: 6178461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The sensitivity of ultrasound and serum alpha-fetoprotein in population-based antenatal screening for neural tube defects. South Australia 1986-1991.
    Chan A; Robertson EF; Haan EA; Ranieri E; Keane RJ
    Br J Obstet Gynaecol; 1995 May; 102(5):370-6. PubMed ID: 7542023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prenatal diagnosis of neural tube defects. IV. Maternal serum alpha-fetoprotein screening.
    Milunsky A; Alpert E; Neff RK; Frigoletto FD
    Obstet Gynecol; 1980 Jan; 55(1):60-6. PubMed ID: 6153240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Routine assessment of amniotic fluid alpha-Fetoprotein in early second-trimester amniocentesis is no longer justified.
    Widlund KF; Gottvall T
    Acta Obstet Gynecol Scand; 2007; 86(2):167-71. PubMed ID: 17364279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prenatal screening for Down's syndrome with use of maternal serum markers.
    Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB
    N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal serum alpha-fetoprotein screening: a cost-benefit analysis.
    Layde PM; von Allmen SD; Oakley GP
    Am J Public Health; 1979 Jun; 69(6):566-73. PubMed ID: 87134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal serum alpha-fetoprotein screening for the detection of neural tube defects.
    Crandall BF; Robertson RD; Lebherz TB; King W; Schroth PC
    West J Med; 1983 Apr; 138(4):524-30. PubMed ID: 6191442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prenatal diagnosis policy without routine amniocentesis in pregnancies with a positive family history for neural tube defects.
    Papp Z; Tóth Z; Török O; Szabó M
    Am J Med Genet; 1987 Jan; 26(1):103-10. PubMed ID: 2433941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of antenatal diagnosis and selective abortion on frequencies of genetic disorders.
    Motulsky AG; Fraser GR
    Clin Obstet Gynaecol; 1980 Apr; 7(1):121-33. PubMed ID: 6155236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal alpha-fetoprotein screening: two years' experience in a low-risk district.
    Standing SJ; Brindle MJ; Macdonald AP; Lacey RW
    Br Med J (Clin Res Ed); 1981 Sep; 283(6293):705-7. PubMed ID: 6169386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maternal serum alpha-fetoprotein screening: benefits, risks, and costs.
    Campbell TL
    J Fam Pract; 1987 Nov; 25(5):461-7. PubMed ID: 2445897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neural tube defects: maternal serum screening and prenatal diagnosis.
    Crandall BF; Lebherz TB; Freihube R
    Pediatr Clin North Am; 1978 Aug; 25(3):619-29. PubMed ID: 80780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maternal serum alpha-fetoprotein screening in a provincial Health District.
    Woolfson J; Holt EM; Whyman AE; Mabbs DV
    Br J Obstet Gynaecol; 1979 Feb; 86(2):87-90. PubMed ID: 85461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
    McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
    J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results and benefits of a maternal serum alpha-fetoprotein screening program.
    Milunsky A; Alpert E
    JAMA; 1984 Sep; 252(11):1438-42. PubMed ID: 6206249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prenatal biochemical screening for Down's syndrome and neural tube defects.
    Wald NJ; Kennard A
    Curr Opin Obstet Gynecol; 1992 Apr; 4(2):302-7. PubMed ID: 1373963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A.
    Haddow JE; Palomaki GE; Knight GJ; Foster DL; Neveux LM
    J Med Screen; 1998; 5(3):115-9. PubMed ID: 9795869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal serum screening for Down's syndrome, open neural tube defects and trisomy 18.
    Akbas SH; Ozben T; Alper O; Ugur A; Yücel G; Lüleci G
    Clin Chem Lab Med; 2001 Jun; 39(6):487-90. PubMed ID: 11506458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal serum screening in Ontario using the triple marker test.
    Summers AM; Farrell SA; Huang T; Meier C; Wyatt PR
    J Med Screen; 2003; 10(3):107-11. PubMed ID: 14561260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of need for amniocentesis in patients with elevated levels of maternal serum alpha-fetoprotein and normal ultrasonographic examinations.
    Nadel AS; Green JK; Holmes LB; Frigoletto FD; Benacerraf BR
    N Engl J Med; 1990 Aug; 323(9):557-61. PubMed ID: 1696358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.